A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 01 2021
Historique:
received: 24 08 2020
accepted: 06 01 2021
entrez: 20 1 2021
pubmed: 21 1 2021
medline: 7 10 2021
Statut: epublish

Résumé

Acute-on-chronic liver failure (ACLF) is a dynamic syndrome, and sequential assessments can reflect its prognosis more accurately. Our aim was to build and validate a new scoring system to predict short-term prognosis using baseline and dynamic data in ACLF. We conducted a retrospective cohort analysis of patients with ACLF from three different hospitals in China. To construct the model, we analyzed a training set of 541 patients from two hospitals. The model's performance was evaluated in a validation set of 130 patients from another center. In the training set, multivariate Cox regression analysis revealed that age, WGO type, basic etiology, total bilirubin, creatinine, prothrombin activity, and hepatic encephalopathy stage were all independent prognostic factors in ACLF. We designed a dynamic trend score table based on the changing trends of these indicators. Furthermore, a logistic prediction model (DP-ACLF) was constructed by combining the sum of dynamic trend scores and baseline prognostic parameters. All prognostic scores were calculated based on the clinical data of patients at the third day, first week, and second week after admission, respectively, and were correlated with the 90-day prognosis by ROC analysis. Comparative analysis showed that the AUC value for DP-ACLF was higher than for other prognostic scores, including Child-Turcotte-Pugh, MELD, MELD-Na, CLIF-SOFA, CLIF-C ACLF, and COSSH-ACLF. The new scoring model, which combined baseline characteristics and dynamic changes in clinical indicators to predict the course of ACLF, showed a better prognostic ability than current scoring systems. Prospective studies are needed to validate these results.

Identifiants

pubmed: 33469110
doi: 10.1038/s41598-021-81431-0
pii: 10.1038/s41598-021-81431-0
pmc: PMC7815739
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1810

Références

Hepatology. 2020 Sep;72(3):1109-1116
pubmed: 32416642
Hepatology. 2007 Mar;45(3):797-805
pubmed: 17326206
Hepatology. 2018 Oct;68(4):1621-1632
pubmed: 29689120
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
Intensive Care Med. 2020 Jan;46(1):1-16
pubmed: 31588983
Gastroenterology. 2006 May;130(6):1652-60
pubmed: 16697729
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):131-49
pubmed: 26837712
Gastroenterology. 2012 Apr;142(4):782-789.e3
pubmed: 22248661
Hepatology. 2014 Jul;60(1):250-6
pubmed: 24677131
Gut. 2018 Dec;67(12):2181-2191
pubmed: 28928275
Dig Liver Dis. 2020 Jan;52(1):91-97
pubmed: 31542220
Hepatology. 2002 Mar;35(3):716-21
pubmed: 11870389
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Hepatol Int. 2017 Sep;11(5):461-471
pubmed: 28856540
Hepatol Int. 2019 Jul;13(4):353-390
pubmed: 31172417
Crit Care. 2012 Nov 27;16(6):R227
pubmed: 23186071
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Gut. 2017 Mar;66(3):541-553
pubmed: 28053053
Clin Mol Hepatol. 2015 Sep;21(3):232-41
pubmed: 26523268
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
Gastroenterology. 2014 Jul;147(1):4-10
pubmed: 24853409
Gastroenterol Rep (Oxf). 2015 May;3(2):122-7
pubmed: 25391261
Aliment Pharmacol Ther. 2018 Oct;48(7):750-760
pubmed: 30069888
J Clin Gastroenterol. 2019 Feb;53(2):134-141
pubmed: 29369242
J Gastroenterol Hepatol. 2021 Jan;36(1):208-216
pubmed: 32445263

Auteurs

Zhenjun Yu (Z)

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University, No. 83, Jintang Road, Hedong District, Tianjin, 300170, China.

Yu Zhang (Y)

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University, No. 83, Jintang Road, Hedong District, Tianjin, 300170, China.

Yingying Cao (Y)

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University, No. 83, Jintang Road, Hedong District, Tianjin, 300170, China.

Manman Xu (M)

Liver Disease Center (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.

Shaoli You (S)

Liver Failure Treatment and Research Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.

Yu Chen (Y)

Liver Disease Center (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.

Bing Zhu (B)

Liver Failure Treatment and Research Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.

Ming Kong (M)

Liver Disease Center (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China.

Fangjiao Song (F)

Liver Failure Treatment and Research Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China.

Shaojie Xin (S)

Liver Failure Treatment and Research Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China. xinshaojie302@163.com.

Zhongping Duan (Z)

Liver Disease Center (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing You'an Hospital Affiliated to Capital Medical University, Beijing, China. duan2517@163.com.

Tao Han (T)

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University, No. 83, Jintang Road, Hedong District, Tianjin, 300170, China. hantaomd@126.com.
Department of Hepatology and Gastroenterology, Tianjin Third Central Hospital Affiliated to Nankai University, Tianjin, China. hantaomd@126.com.
Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, The Tianjin Third Central Hospital, Tianjin, China. hantaomd@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH